HK Stock Market Move | BOAN BIOTECH (06955) surged over 8% in late trading; BA1203 received approval from the National Medical Products Administration to conduct clinical trials.

BOAN BIOTECH (06955) rose over 8% in late trading. As of press time, it was up 7.66% at HK$2.95, with a turnover of HK$2.9376 million. On the news front, BOAN BIOTECH recently announced that the Investigational New Drug (IND) application for its investigational PD-1/IL-2 antibody cytokine prodrug BA1203 has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, with the intended development for the treatment of multiple solid tumors. To the company's knowledge, this investigational drug is the world's only IL-2 receptor high-activity, masked, and PD-1-blocking PD-1/IL-2 molecule. Following this approval to enter clinical trials, BOAN BIOTECH plans to conduct a multicenter, open-label Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BA1203 in patients with advanced solid tumors, further validating its advantages in efficacy and safety, and exploring its development path as a monotherapy and in combination therapy, to fully unlock BA1203's differentiated therapeutic potential in PD-1 target binding, immune pathway blockade, and tumor microenvironment immune activation.